This product is an anti-deoxyribonucleic acid (DNA) virus drug. Its pharmacological action is to bind to the viral deoxyribonucleic acid polymerase, reduce its activity and inhibit DNA synthesis. After entering the cell, adenosine monophosphate is phosphorylated to generate adenosine diphosphate (Ara-ADP) and adenosine triphosphate (Ara-ATP). The antiviral activity is mainly caused by adenosine triphosphate (Ara-ATP). Ara-ATP and deoxyadenosine triphosphate (dATP) compete to bind to viral DNAP, thereby inhibiting the activity of the enzyme and the synthesis of viral DNA. At the same time, it inhibits the activity of viral nucleotide reductase and inhibits the synthesis of viral DNA. It can also inhibit the activity of viral DNA terminal deoxynucleotidyl transferase, so that Ara-A penetrates into the viral DNA and connects to the end of the DNA chain 3prime;-OH position, inhibiting the continued synthesis of viral DNA.

This product is an anti-deoxyribonucleic acid (DNA) virus drug. Its pharmacological action is to bind to the viral deoxyribonucleic acid polymerase, reduce its activity and inhibit DNA synthesis. After entering the cell, adenosine monophosphate is phosphorylated to generate adenosine diphosphate (Ara-ADP) and adenosine triphosphate (Ara-ATP). The antiviral activity is mainly caused by adenosine triphosphate (Ara-ATP). Ara-ATP and deoxyadenosine triphosphate (dATP) compete to bind to viral DNAP, thereby inhibiting the activity of the enzyme and the synthesis of viral DNA. At the same time, it inhibits the activity of viral nucleotide reductase and inhibits the synthesis of viral DNA. It can also inhibit the activity of viral DNA terminal deoxynucleotidyl transferase, so that Ara-A penetrates into the viral DNA and connects to the end of the DNA chain 3prime;-OH position, inhibiting the continued synthesis of viral DNA.

Proteolytic enzyme. It can dissolve blood clots, inhibit thrombosis, and improve microcirculation.

Proteolytic enzyme. It can dissolve blood clots, inhibit thrombosis, and improve microcirculation.

Selective (cardioselective) β1 adrenergic receptor blocker, with rapid onset, short duration of action, and no obvious intrinsic sympathomimetic activity or membrane stabilizing effect at therapeutic doses. The elimination half-life after intravenous injection is about 9 minutes. It mainly inhibits β1 adrenergic receptors located in the myocardium, and in large doses also has a blocking effect on β2 adrenergic receptors in tracheal and vascular smooth muscle.